awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34056295-13DCAE65-10F0-42A9-B8EC-FDE90016E50D
Q34056295-13DCAE65-10F0-42A9-B8EC-FDE90016E50D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34056295-13DCAE65-10F0-42A9-B8EC-FDE90016E50D
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
P2860
Q34056295-13DCAE65-10F0-42A9-B8EC-FDE90016E50D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34056295-13DCAE65-10F0-42A9-B8EC-FDE90016E50D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
20cd7fa134511f38673e57f8a2a157c3ec40a7b3
P2860
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.